About: COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients With Chronic Kidney Disease and Renal Transplantation

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients With Chronic Kidney Disease and Renal Transplantation Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients With Chronic Kidney Disease and Renal Transplantation
Creator	Adapa, Sreedhar Balla, Mamtha Chenna, Avantika Gayam, Vijay Konala, Venu Merugu, Ganesh Naramala, Srikanth Koduri, Narayana Rao Daggubati, Subba
source	Medline; PMC; WHO
abstract	Coronavirus disease 2019 (COVID-19) caused by 2019 novel coronavirus (2019-nCoV) has caused significant mortality and has been declared as a global pandemic by the World Health Organization. The infection mainly presents as fever, cough, and breathing difficulty, and few patients develop very severe symptoms. The purpose of this review is to analyze the impact of the virus on the kidney. COVID-19 infection causes acute kidney injury (AKI) and is an independent risk factor for mortality. Angiotensin-converting enzyme 2 (ACE2) receptors, direct viral damage, and immune-mediated damage play important roles in the pathogenesis. AKI in COVID-19 infection could be from the synergistic effect of virus-induced direct cytotropic effect and cytokine-induced systemic inflammatory response. AKI caused in the viral infection has been analyzed from the available epidemiological studies. The proportion of patients developing AKI is significantly higher when they develop severe disease. Continuous renal replacement therapy (CRRT) is the most used blood purification technique when needed. The impact of COVID-19 infection on chronic kidney disease (CKD) and renal transplant patients is also discussed in the manuscript. No vaccine has been developed against the 2019-nCoV virus to date. The critical aspect of management is supportive care. Several investigative drugs have been studied, drugs approved for other indications have been used, and several clinical trials are underway across the globe. Recently remdesivir has received emergency use authorization by the Food and Drug Administration (FDA) in the USA for use in patients hospitalized with COVID-19. Prevention of the infection holds the key to management. The patients with underlying kidney problems and renal transplant patients are vulnerable to developing COVID-19 infection.
has issue date	2020-06-04(xsd:dateTime)
bibo:doi	10.14740/jocmr4200
bibo:pmid	32587651
has license	cc-by-nc
sha1sum (hex)	f647e95eae6b39ffdf2cdf37a41c129f8605723d
schema:url	https://doi.org/10.14740/jocmr4200
resource representing a document's title	COVID-19 Pandemic Causing Acute Kidney Injury and Impact on Patients With Chronic Kidney Disease and Renal Transplantation
has PubMed Central identifier	PMC7295554
has PubMed identifier	32587651
schema:publication	J Clin Med Res
resource representing a document's body	covid:f647e95eae6b39ffdf2cdf37a41c129f8605723d#body_text
is schema:about of	named entity 'clinical trials' named entity 'infection' named entity 'Drug' named entity 'pathogenesis' named entity 'presents' named entity 'mortality' named entity 'USA' named entity 'COVID-19' named entity 'World Health Organization' named entity 'develop' named entity 'The' named entity 'The infection' named entity 'COVID-19' named entity 'patients' named entity 'MANUSCRIPT' named entity 'AKI' named entity 'VULNERABLE' named entity 'DAMAGE' named entity 'indications' named entity 'epidemiological studies' named entity 'severe' named entity 'Continuous' named entity 'immune-mediated' named entity 'drugs' named entity 'authorization' named entity 'patients' named entity 'higher' named entity 'viral' named entity 'Angiotensin-converting enzyme 2' named entity 'studied' named entity 'infection' named entity 'vaccine' named entity 'key' named entity 'critical' named entity 'coronavirus' named entity 'needed' named entity 'Injury' named entity 'With' named entity 'kidney problems' named entity 'Coronavirus disease 2019' named entity 'COVID-19' named entity 'ACE2' named entity 'cytokine' named entity 'fever' named entity 'renal transplant' named entity '2019-nCoV' named entity 'immune-mediated' named entity 'coronavirus' named entity 'Acute Kidney Injury' named entity 'global' named entity 'globe' named entity 'The' named entity 'virus' named entity 'COVID-19' named entity 'macrophage' named entity 'hydroxychloroquine' named entity 'ritonavir/lopinavir' named entity 'proteinuria' named entity 'darunavir' named entity 'virulence' named entity 'clinical trial' named entity 'clinical practice' named entity 'Middle Eastern respiratory syndrome' named entity 'podocyte' named entity 'aspartate' named entity 'COVID-19' named entity 'estimated glomerular filtration rate' named entity 'COVID-19' named entity 'autopsy' named entity 'infection' named entity 'COVID' named entity 'drug-drug interactions' named entity 'AKI'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software